SEPN
NASDAQ HealthcareSepterna, Inc. - Common Stock
Biotechnology
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
�� 市场数据
| 价格 | $26.13 |
|---|---|
| 成交量 | 379,455 |
| 市值 | 1.17B |
| RSI（14日） | 61.0 |
| 200日均线 | $21.29 |
| 50日均线 | $26.14 |
| 52周最高 | $32.63 |
| 52周最低 | $5.73 |
| Forward P/E | -13.43 |
| Price / Book | 3.07 |
🎯 投资策略评分
SEPN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (46/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🚀 Moon Shot (11/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 SEPN in your text
粘贴任何文章、记录或帖子 — 工具将提取 SEPN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.